## Nicholas M Anstey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3444999/publications.pdf Version: 2024-02-01

		16451	22166
237	15,666	64	113
papers	citations	h-index	g-index
242	242	242	12480
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in <i>Plasmodium knowlesi</i> Malaria (PACKNOW): A Randomized, Controlled Trial. Clinical Infectious Diseases, 2022, 75, 1379-1388.	5.8	10
2	Positron emission tomography and magnetic resonance imaging of the brain in experimental human malaria, a prospective cohort study. Scientific Reports, 2022, 12, 5696.	3.3	1
3	Diagnostic performance of a 5-plex malaria immunoassay in regions co-endemic for Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae and P. ovale. Scientific Reports, 2022, 12, 7286.	3.3	6
4	Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P.Âknowlesi. Cell Reports Medicine, 2022, 3, 100662.	6.5	6
5	Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity. PLoS Neglected Tropical Diseases, 2022, 16, e0010492.	3.0	2
6	Reduced circulating dendritic cells in acute Plasmodium knowlesi and Plasmodium falciparum malaria despite elevated plasma Flt3 ligand levels. Malaria Journal, 2021, 20, 97.	2.3	3
7	An Evaluation of Commonly Used Surrogate Baseline Creatinine Values to Classify AKI During Acute Infection. Kidney International Reports, 2021, 6, 645-656.	0.8	22
8	Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study. PLoS Medicine, 2021, 18, e1003632.	8.4	60
9	Endothelial glycocalyx degradation and disease severity in Plasmodium vivax and Plasmodium knowlesi malaria. Scientific Reports, 2021, 11, 9741.	3.3	6
10	Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study. PLoS Medicine, 2021, 18, e1003567.	8.4	6
11	Hidden Biomass of Intact Malaria Parasites in the Human Spleen. New England Journal of Medicine, 2021, 384, 2067-2069.	27.0	82
12	The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infectious Diseases, The, 2021, 21, 1737-1746.	9.1	58
13	Degradation of endothelial glycocalyx in Tanzanian children with falciparum malaria. FASEB Journal, 2021, 35, e21805.	0.5	5
14	Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 46-56.	3.4	4
15	Plasmodium knowlesi detection methods for human infections—Diagnosis and surveillance. Advances in Parasitology, 2021, 113, 77-130.	3.2	7
16	Clinical management of Plasmodium knowlesi malaria. Advances in Parasitology, 2021, 113, 45-76.	3.2	15
17	Knowlesi malaria: Human risk factors, clinical spectrum, and pathophysiology. Advances in Parasitology, 2021, 113, 1-43.	3.2	14
18	<i>&gt;Plasmodium knowlesi</i> Malaria in Sabah, Malaysia, 2015–2017: Ongoing Increase in Incidence Despite Near-elimination of the Human-only <i>Plasmodium</i> Species. Clinical Infectious Diseases, 2020, 70, 361-367.	5.8	97

#	Article	IF	CITATIONS
19	The impact of delayed treatment of uncomplicated P. falciparum malaria on progression to severe malaria: A systematic review and a pooled multicentre individual-patient meta-analysis. PLoS Medicine, 2020, 17, e1003359.	8.4	50
20	Comparative evaluation of two commercial real-time PCR kits (QuantiFastâ,,¢ and abTESâ,,¢) for the detection of Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia. Malaria Journal, 2020, 19, 306.	2.3	14
21	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	3.8	3
22	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008295.	3.0	9
23	Transcriptional profiling and immunophenotyping show sustained activation of blood monocytes in subpatent <i>Plasmodium falciparum</i> infection. Clinical and Translational Immunology, 2020, 9, e1144.	3.8	13
24	Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity. PLoS Neglected Tropical Diseases, 2020, 14, e0008202.	3.0	5
25	Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study. PLoS ONE, 2020, 15, e0228018.	2.5	3
26	Safety and Outcomes of Linezolid Use for Nocardiosis. Open Forum Infectious Diseases, 2020, 7, ofaa090.	0.9	20
27	Early Endothelial Activation Precedes Glycocalyx Degradation and Microvascular Dysfunction in Experimentally Induced Plasmodium falciparum and Plasmodium vivax Infection. Infection and Immunity, 2020, 88, .	2.2	12
28	2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Neglected Tropical Diseases, 2020, 14, e0008659.	3.0	73
29	The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008838.	3.0	10
30	Liver Function Test Abnormalities in Experimental and Clinical Plasmodium vivax Infection. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1910-1917.	1.4	16
31	High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. Clinical Infectious Diseases, 2019, 68, 51-60.	5.8	11
32	Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 31± and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. Journal of Infectious Diseases, 2019, 220, 1950-1961.	4.0	15
33	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
34	Whole genome sequencing of amplified Plasmodium knowlesi DNA from unprocessed blood reveals genetic exchange events between Malaysian Peninsular and Borneo subpopulations. Scientific Reports, 2019, 9, 9873.	3.3	25
35	Whole-Genome Sequencing to Differentiate Relapse From Reinfection in Community-Onset Bacteremic Acinetobacter baumannii Pneumonia. Open Forum Infectious Diseases, 2019, 6, ofz263.	0.9	3
36	Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Medicine, 2019, 16, e1002815.	8.4	38

#	Article	IF	CITATIONS
37	Antiphosphatidylserine Immunoglobulin M and Immunoglobulin G Antibodies Are Higher in Vivax Than Falciparum Malaria, and Associated With Early Anemia in Both Species. Journal of Infectious Diseases, 2019, 220, 1435-1443.	4.0	26
38	Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infectious Diseases, 2019, 19, 922.	2.9	18
39	Glycocalyx breakdown is increased in African children with cerebral and uncomplicated falciparum malaria. FASEB Journal, 2019, 33, 14185-14193.	0.5	18
40	Loss of complement regulatory proteins on red blood cells in mild malarial anaemia and in Plasmodium falciparum induced blood-stage infection. Malaria Journal, 2019, 18, 312.	2.3	7
41	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
42	Genomic Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective Pressures in Multiple Parasite Mechanisms. Journal of Infectious Diseases, 2019, 220, 1738-1749.	4.0	50
43	Environmental risk factors and exposure to the zoonotic malaria parasite Plasmodium knowlesi across northern Sabah, Malaysia: a population-based cross-sectional survey. Lancet Planetary Health, The, 2019, 3, e179-e186.	11.4	75
44	Predictive analysis across spatial scales links zoonotic malaria to deforestation. Proceedings of the Royal Society B: Biological Sciences, 2019, 286, 20182351.	2.6	51
45	Glycocalyx Breakdown Is Associated With Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2019, 69, 1712-1720.	5.8	31
46	Cell-Free Hemoglobin Is Associated With Increased Vascular Resistance and Reduced Peripheral Perfusion in Severe Malaria. Journal of Infectious Diseases, 2019, 221, 127-137.	4.0	4
47	Novel RNA viruses associated with Plasmodium vivax in human malaria and Leucocytozoon parasites in avian disease. PLoS Pathogens, 2019, 15, e1008216.	4.7	50
48	Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria. Journal of Infectious Diseases, 2019, 219, 1994-2004.	4.0	46
49	Deaths From Plasmodium knowlesi Malaria: Case Series and Systematic Review. Clinical Infectious Diseases, 2019, 69, 1703-1711.	5.8	57
50	Zoonotic Malaria: The Better You Look, the More You Find. Journal of Infectious Diseases, 2019, 219, 679-681.	4.0	22
51	Case Report: Severe Disseminated Gonococcal Infection with Polyarticular Gout: Two Cases in Older Travelers. American Journal of Tropical Medicine and Hygiene, 2019, 100, 209-212.	1.4	5
52	The effect of regularly dosed paracetamol versus no paracetamol on renal function in Plasmodium knowlesi malaria (PACKNOW): study protocol for a randomised controlled trial. Trials, 2018, 19, 250.	1.6	15
53	Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clinical Infectious Diseases, 2018, 67, 991-999.	5.8	44
54	Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. Clinical Infectious Diseases, 2018, 66, 229-236.	5.8	26

#	Article	IF	CITATIONS
55	Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia. JCI Insight, 2018, 3, .	5.0	20
56	Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance. Malaria Journal, 2018, 17, 463.	2.3	8
57	Laboratory challenges of Plasmodium species identification in Aceh Province, Indonesia, a malaria elimination setting with newly discovered P. knowlesi. PLoS Neglected Tropical Diseases, 2018, 12, e0006924.	3.0	22
58	Reduced red blood cell deformability in Plasmodium knowlesi malaria. Blood Advances, 2018, 2, 433-443.	5.2	34
59	Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics. Nature Communications, 2018, 9, 2585.	12.8	59
60	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	9.1	85
61	Platelets kill circulating parasites of all major Plasmodium species in human malaria. Blood, 2018, 132, 1332-1344.	1.4	85
62	Intravascular haemolysis in severe <i>Plasmodium knowlesi</i> malaria: association with endothelial activation, microvascular dysfunction, and acute kidney injury. Emerging Microbes and Infections, 2018, 7, 1-10.	6.5	43
63	Age-Related Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of Severity. Clinical Infectious Diseases, 2018, 67, 350-359.	5.8	78
64	Identification and validation of a novel panel of Plasmodium knowlesi biomarkers of serological exposure. PLoS Neglected Tropical Diseases, 2018, 12, e0006457.	3.0	26
65	The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen–encoding var genes. PLoS Biology, 2018, 16, e2004328.	5.6	67
66	Therapeutic Response to Dihydroartemisinin–Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 677-682.	1.4	23
67	Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 543-550.	1.4	17
68	Antibiotic Therapy in Adults with Malaria (ANTHEM): High Rate of Clinically Significant Bacteremia in Hospitalized Adults Diagnosed with Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2018, 99, 688-696.	1.4	23
69	Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature, 2017, 542, 101-104.	27.8	150
70	Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c <sup>+</sup> Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation. Infection and Immunity, 2017, 85, .	2.2	22
71	Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation. Scientific Reports, 2017, 7, 2596.	3.3	24
72	Effects of Aging on Parasite Biomass, Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in <i>Plasmodium knowlesi</i> and <i>Plasmodium falciparum</i> Malaria. Journal of Infectious Diseases, 2017, 215, 1908-1917.	4.0	34

#	Article	IF	CITATIONS
73	Individual-level factors associated with the risk of acquiring human Plasmodium knowlesi malaria in Malaysia: a case-control study. Lancet Planetary Health, The, 2017, 1, e97-e104.	11.4	99
74	Cell-free hemoglobin mediated oxidative stress is associated with acute kidney injury and renal replacement therapy in severe falciparum malaria: an observational study. BMC Infectious Diseases, 2017, 17, 313.	2.9	72
75	Detection of Plasmodium knowlesi, Plasmodium falciparum and Plasmodium vivax using loop-mediated isothermal amplification (LAMP) in a co-endemic area in Malaysia. Malaria Journal, 2017, 16, 29.	2.3	40
76	World Malaria Report: time to acknowledge Plasmodium knowlesi malaria. Malaria Journal, 2017, 16, 135.	2.3	97
77	The Treatment of Plasmodium knowlesi Malaria. Trends in Parasitology, 2017, 33, 242-253.	3.3	47
78	Disease Severity and Effective Parasite Multiplication Rate in Falciparum Malaria. Open Forum Infectious Diseases, 2017, 4, ofx169.	0.9	12
79	Genomic Characterization of Recrudescent <i>Plasmodium malariae</i> after Treatment with Artemether/Lumefantrine. Emerging Infectious Diseases, 2017, 23, 1300-1307.	4.3	36
80	Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Medicine, 2017, 14, e1002379.	8.4	74
81	Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1788-1796.	1.4	16
82	Falling <i>Plasmodium knowlesi</i> Malaria Death Rate among Adults despite Rising Incidence, Sabah, Malaysia, 2010–2014. Emerging Infectious Diseases, 2016, 22, 41-8.	4.3	58
83	Intravascular haemolysis with haemoglobinuria in a splenectomized patient with severe Plasmodium knowlesi malaria. Malaria Journal, 2016, 15, 462.	2.3	15
84	Sensitive Detection of Plasmodium vivax Using a High-Throughput, Colourimetric Loop Mediated Isothermal Amplification (HtLAMP) Platform: A Potential Novel Tool for Malaria Elimination. PLoS Neglected Tropical Diseases, 2016, 10, e0004443.	3.0	38
85	Transfusion-transmitted severe Plasmodium knowlesi malaria in a splenectomized patient with beta-thalassaemia major in Sabah, Malaysia: a case report. Malaria Journal, 2016, 15, 357.	2.3	15
86	MALDI-TOF MS for identification of community-acquired Acinetobacter baumannii complex infections. Pathology, 2016, 48, 100-102.	0.6	3
87	Efficacy of Artesunate-mefloquine for Chloroquine-resistantPlasmodium vivaxMalaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clinical Infectious Diseases, 2016, 62, 1403-1411.	5.8	44
88	A Sensitive, Colorimetric, High-Throughput Loop-Mediated Isothermal Amplification Assay for the Detection of Plasmodium knowlesi. American Journal of Tropical Medicine and Hygiene, 2016, 95, 120-122.	1.4	21
89	Nitric Oxide–Dependent Endothelial Dysfunction and Reduced Arginine Bioavailability in Plasmodium vivax Malaria but No Greater Increase in Intravascular Hemolysis in Severe Disease. Journal of Infectious Diseases, 2016, 214, 1557-1564.	4.0	19
90	High Frequency of Clinically Significant Bacteremia in Adults Hospitalized With Falciparum Malaria. Open Forum Infectious Diseases, 2016, 3, ofw028.	0.9	26

#	Article	IF	CITATIONS
91	Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nature Genetics, 2016, 48, 959-964.	21.4	169
92	Asymptomatic and Submicroscopic Carriage of <i>Plasmodium knowlesi</i> Malaria in Household and Community Members of Clinical Cases in Sabah, Malaysia. Journal of Infectious Diseases, 2016, 213, 784-787.	4.0	64
93	Asymmetric Dimethylarginine in Adult Falciparum Malaria: Relationships With Disease Severity, Antimalarial Treatment, Hemolysis, and Inflammation. Open Forum Infectious Diseases, 2016, 3, ofw027.	0.9	13
94	Profoundly Reduced CD1c <sup>+</sup> Myeloid Dendritic Cell HLA-DR and CD86 Expression and Increased Tumor Necrosis Factor Production in Experimental Human Blood-Stage Malaria Infection. Infection and Immunity, 2016, 84, 1403-1412.	2.2	22
95	Pharmacokinetic-Pharmacodynamic Model for the Effect of <scp>l</scp> -Arginine on Endothelial Function in Patients with Moderately Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2016, 60, 198-205.	3.2	11
96	Retinal Changes in Uncomplicated and SeverePlasmodium knowlesiMalaria. Journal of Infectious Diseases, 2016, 213, 1476-1482.	4.0	11
97	Artesunate–mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2016, 16, 180-188.	9.1	58
98	Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS ONE, 2016, 11, e0149519.	2.5	17
99	Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. PLoS ONE, 2016, 11, e0160917.	2.5	16
100	Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia. PLoS ONE, 2016, 11, e0165340.	2.5	48
101	Severe falciparum malaria treated with artesunate complicated by delayed onset haemolysis and acute kidney injury. Malaria Journal, 2015, 14, 246.	2.3	27
102	Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malaria Journal, 2015, 14, 272.	2.3	13
103	Fever and rash from Timor: where have you been and when?. Medical Journal of Australia, 2015, 203, 338-338.	1.7	2
104	The Safety of a Conservative Fluid Replacement Strategy in Adults Hospitalised with Malaria. PLoS ONE, 2015, 10, e0143062.	2.5	15
105	A Prospective Study of Tuberculosis Drug Susceptibility in Sabah, Malaysia, and an Algorithm for Management of Isoniazid Resistance. Journal of Tropical Medicine, 2015, 2015, 1-8.	1.7	6
106	Severe Malarial Thrombocytopenia: A Risk Factor for Mortality in Papua, Indonesia. Journal of Infectious Diseases, 2015, 211, 623-634.	4.0	55
107	A prospective study of mycobacterial viability in refrigerated, unpreserved sputum batched for up to 8 weeks. International Journal of Tuberculosis and Lung Disease, 2015, 19, 620-621.	1.2	4
108	<i>Plasmodium knowlesi</i> Malaria During Pregnancy. Journal of Infectious Diseases, 2015, 211, 1104-1110.	4.0	20

#	Article	IF	CITATIONS
109	Preserved Dendritic Cell HLA-DR Expression and Reduced Regulatory T Cell Activation in Asymptomatic Plasmodium falciparum and P. vivax Infection. Infection and Immunity, 2015, 83, 3224-3232.	2.2	27
110	Parasite Biomass-Related Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Vivax Malaria. PLoS Pathogens, 2015, 11, e1004558.	4.7	120
111	Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Oxidized Biopterins in Pediatric Falciparum Malaria: Association with Disease Severity. PLoS Pathogens, 2015, 11, e1004655.	4.7	29
112	Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Dihydrobiopterin in Adult Falciparum Malaria: Association with Disease Severity, Impaired Microvascular Function and Increased Endothelial Activation. PLoS Pathogens, 2015, 11, e1004667.	4.7	33
113	Intravenous Therapy Duration and Outcomes in Melioidosis: A New Treatment Paradigm. PLoS Neglected Tropical Diseases, 2015, 9, e0003586.	3.0	83
114	Pulmonary tuberculosis in outpatients in Sabah, Malaysia: advanced disease but low incidence of HIV co-infection. BMC Infectious Diseases, 2015, 15, 32.	2.9	14
115	The prognostic utility of bedside assessment of adults hospitalized with malaria in Myanmar: a retrospective analysis. Malaria Journal, 2015, 14, 63.	2.3	7
116	Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Medicine, 2015, 13, 122.	5.5	62
117	Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Neglected Tropical Diseases, 2015, 9, e0004195.	3.0	71
118	ZIKA VIRUS INFECTION IN AUSTRALIA FOLLOWING A MONKEY BITE IN INDONESIA. Southeast Asian Journal of Tropical Medicine and Public Health, 2015, 46, 460-4.	1.0	87
119	Changing epidemiology of malaria in Sabah, Malaysia: increasing incidence of Plasmodium knowlesi. Malaria Journal, 2014, 13, 390.	2.3	107
120	Decreased Endothelial Nitric Oxide Bioavailability, Impaired Microvascular Function, and Increased Tissue Oxygen Consumption in Children with Falciparum Malaria. Journal of Infectious Diseases, 2014, 210, 1627-1632.	4.0	38
121	Defining the Geographical Range of the Plasmodium knowlesi Reservoir. PLoS Neglected Tropical Diseases, 2014, 8, e2780.	3.0	84
122	Quantification of Plasmodium falciparum Histidine-Rich Protein-2 in Cerebrospinal Spinal Fluid from Cerebral Malaria Patients. American Journal of Tropical Medicine and Hygiene, 2014, 91, 486-492.	1.4	10
123	Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia. BMC Medicine, 2014, 12, 217.	5.5	80
124	The fluid management of adults with severe malaria. Critical Care, 2014, 18, 642.	5.8	30
125	Increased plasma arginase activity in human sepsis: association with increased circulating neutrophils. Clinical Chemistry and Laboratory Medicine, 2014, 52, 573-81.	2.3	22
126	Effect of Periodontal Therapy on Arterial Structure and Function Among Aboriginal Australians. Hypertension, 2014, 64, 702-708.	2.7	47

#	Article	IF	CITATIONS
127	Combining Parasite Lactate Dehydrogenase-Based and Histidine-Rich Protein 2-Based Rapid Tests To Improve Specificity for Diagnosis of Malaria Due to Plasmodium knowlesi and Other Plasmodium Species in Sabah, Malaysia. Journal of Clinical Microbiology, 2014, 52, 2053-2060.	3.9	46
128	A 16-Year Prospective Study of Community-Onset Bacteremic Acinetobacter Pneumonia. Chest, 2014, 146, 1038-1045.	0.8	56
129	Dihydroartemisinin-Piperaquine Treatment of Multidrug Resistant Falciparum and Vivax Malaria in Pregnancy. PLoS ONE, 2014, 9, e84976.	2.5	37
130	Rapid Clinical Assessment to Facilitate the Triage of Adults with Falciparum Malaria, a Retrospective Analysis. PLoS ONE, 2014, 9, e87020.	2.5	18
131	Long Term Outcomes Following Hospital Admission for Sepsis Using Relative Survival Analysis: A Prospective Cohort Study of 1,092 Patients with 5 Year Follow Up. PLoS ONE, 2014, 9, e112224.	2.5	43
132	Vivax malaria and bacteraemia: a prospective study in Kolkata, India. Malaria Journal, 2013, 12, 176.	2.3	27
133	A clinicopathological correlation of the expression of the angiopoietin-Tie-2 receptor pathway in the brain of adults with Plasmodium falciparum malaria. Malaria Journal, 2013, 12, 50.	2.3	32
134	Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malaria Journal, 2013, 12, 8.	2.3	121
135	Simultaneous determination of multiple amino acids in plasma in critical illness by high performance liquid chromatography with ultraviolet and fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 940, 53-58.	2.3	37
136	Impaired Skeletal Muscle Microvascular Function and Increased Skeletal Muscle Oxygen Consumption in Severe Falciparum Malaria. Journal of Infectious Diseases, 2013, 207, 528-536.	4.0	42
137	A Prospective Comparative Study of Knowlesi, Falciparum, and Vivax Malaria in Sabah, Malaysia: High Proportion With Severe Disease From Plasmodium Knowlesi and Plasmodium Vivax But No Mortality With Early Referral and Artesunate Therapy. Clinical Infectious Diseases, 2013, 56, 383-397.	5.8	207
138	Increasing Incidence of Plasmodium knowlesi Malaria following Control of P. falciparum and P. vivax Malaria in Sabah, Malaysia. PLoS Neglected Tropical Diseases, 2013, 7, e2026.	3.0	132
139	Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study. PLoS Medicine, 2013, 10, e1001575.	8.4	117
140	Evaluation of the Sensitivity of a pLDH-Based and an Aldolase-Based Rapid Diagnostic Test for Diagnosis of Uncomplicated and Severe Malaria Caused by PCR-Confirmed Plasmodium knowlesi, Plasmodium falciparum, and Plasmodium vivax. Journal of Clinical Microbiology, 2013, 51, 1118-1123.	3.9	80
141	Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. Journal of Experimental Medicine, 2013, 210, 1635-1646.	8.5	94
142	L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS ONE, 2013, 8, e70032.	2.5	93
143	Tuberculosis Outcomes in Papua, Indonesia: The Relationship with Different Body Mass Index Characteristics between Papuan and Non-Papuan Ethnic Groups. PLoS ONE, 2013, 8, e76077.	2.5	4
144	Eosinophils in Severe Sepsis in Northern Australia. Critical Care Medicine, 2013, 41, e286-e288.	0.9	8

#	Article	IF	CITATIONS
145	Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing. PLoS ONE, 2013, 8, e53160.	2.5	26
146	A Randomized Pilot Study of L-Arginine Infusion in Severe Falciparum Malaria: Preliminary Safety, Efficacy and Pharmacokinetics. PLoS ONE, 2013, 8, e69587.	2.5	42
147	High Morbidity during Treatment and Residual Pulmonary Disability in Pulmonary Tuberculosis: Under-Recognised Phenomena. PLoS ONE, 2013, 8, e80302.	2.5	70
148	Plasmodium vivax Population Structure and Transmission Dynamics in Sabah Malaysia. PLoS ONE, 2013, 8, e82553.	2.5	45
149	Cardiovascular Disease in the Developing World. Journal of the American College of Cardiology, 2012, 60, 1207-1216.	2.8	385
150	Plasmodium vivax. Advances in Parasitology, 2012, 80, 151-201.	3.2	178
151	Epidemiology of Plasmodium knowlesi malaria in north-east Sabah, Malaysia: family clusters and wide age distribution. Malaria Journal, 2012, 11, 401.	2.3	78
152	Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malaria Journal, 2012, 11, 284.	2.3	80
153	The anaemia of Plasmodium vivax malaria. Malaria Journal, 2012, 11, 135.	2.3	173
154	Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria. Advances in Parasitology, 2012, 80, 271-300.	3.2	28
155	Plasma Plasmodium falciparum Histidine-Rich Protein-2 Concentrations Are Associated with Malaria Severity and Mortality in Tanzanian Children. PLoS ONE, 2012, 7, e35985.	2.5	48
156	Comparative <i>Ex Vivo</i> Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2012, 56, 5258-5263.	3.2	38
157	Severe <i>Plasmodium knowlesi</i> Malaria in a Tertiary Care Hospital, Sabah, Malaysia. Emerging Infectious Diseases, 2011, 17, 1248-1255.	4.3	191
158	Sepsis in the tropical Top End of Australia's Northern Territory: disease burden and impact on Indigenous Australians. Medical Journal of Australia, 2011, 194, 519-524.	1.7	66
159	Asymmetric Dimethylarginine, Endothelial Nitric Oxide Bioavailability and Mortality in Sepsis. PLoS ONE, 2011, 6, e17260.	2.5	61
160	An Observational Cohort Study of the Kynurenine to Tryptophan Ratio in Sepsis: Association with Impaired Immune and Microvascular Function. PLoS ONE, 2011, 6, e21185.	2.5	72
161	<i>Ex Vivo</i> Activity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates of <i>Plasmodium falciparum</i> and <i>P. vivax</i> . Antimicrobial Agents and Chemotherapy, 2011, 55, 961-966.	3.2	53
162	Is plasma arginine concentration decreased in patients with sepsis? A systematic review and meta-analysis*. Critical Care Medicine, 2011, 39, 380-385.	0.9	86

#	Article	IF	CITATIONS
163	<i>Plasmodium knowlesi</i> Malaria in Children. Emerging Infectious Diseases, 2011, 17, 814-820.	4.3	82
164	Plasmodium vivax treatments. Current Opinion in Infectious Diseases, 2011, 24, 578-585.	3.1	44
165	Differential Cellular Recognition of Antigens During Acute Plasmodium falciparum and Plasmodium vivax Malaria. Journal of Infectious Diseases, 2011, 203, 1192-1199.	4.0	7
166	<i>Ex Vivo</i> Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2011, 55, 4461-4464.	3.2	37
167	Granzyme B Expression by CD8+ T Cells Is Required for the Development of Experimental Cerebral Malaria. Journal of Immunology, 2011, 186, 6148-6156.	0.8	178
168	Coma Associated with Microscopy-Diagnosed Plasmodium vivax: A Prospective Study in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2011, 5, e1032.	3.0	44
169	A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax, 2010, 65, 863-869.	5.6	177
170	Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes. Human Genetics, 2010, 127, 163-182.	3.8	23
171	HPLC analysis of asymmetric dimethylarginine, symmetric dimethylarginine, homoarginine and arginine in small plasma volumes using a Gemini-NX column at high pH. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 8-12.	2.3	37
172	Pneumonia risk stratification in tropical Australia: does the SMART OP score apply?. Medical Journal of Australia, 2010, 192, 133-136.	1.7	19
173	Pneumonia risk stratification in tropical Australia: does the SMART OP score apply?. Medical Journal of Australia, 2010, 192, 542-543.	1.7	Ο
174	Greater Endothelial Activation, Weibelâ€Palade Body Release and Host Inflammatory Response to <i>Plasmodium vivax,</i> Compared with <i>Plasmodium falciparum</i> : A Prospective Study in Papua, Indonesia. Journal of Infectious Diseases, 2010, 202, 109-112.	4.0	60
175	Severe Congenital Malaria Acquired in utero. American Journal of Tropical Medicine and Hygiene, 2010, 82, 563-565.	1.4	30
176	A Simple Score to Predict the Outcome of Severe Malaria in Adults. Clinical Infectious Diseases, 2010, 50, 679-685.	5.8	89
177	Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome. PLoS Pathogens, 2010, 6, e1000868.	4.7	70
178	Artemisinin combination therapy for vivax malaria. Lancet Infectious Diseases, The, 2010, 10, 405-416.	9.1	204
179	Relationship of Cellâ€Free Hemoglobin to Impaired Endothelial Nitric Oxide Bioavailability and Perfusion in Severe Falciparum Malaria. Journal of Infectious Diseases, 2009, 200, 1522-1529.	4.0	124
180	Parasite-Dependent Expansion of TNF Receptor II–Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria. PLoS Pathogens, 2009, 5, e1000402.	4.7	118

#	Article	IF	CITATIONS
181	High Deformability of <i>Plasmodium vivax</i> –Infected Red Blood Cells under Microfluidic Conditions. Journal of Infectious Diseases, 2009, 199, 445-450.	4.0	107
182	New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases, 2009, 22, 430-435.	3.1	300
183	The pathophysiology of vivax malaria. Trends in Parasitology, 2009, 25, 220-227.	3.3	347
184	Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study. Critical Care, 2009, 13, R155.	5.8	49
185	Tuberculosis into the 2010s: Is the Glass Half Full?. Clinical Infectious Diseases, 2009, 49, 574-583.	5.8	22
186	L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends in Microbiology, 2008, 16, 336-344.	7.7	53
187	Antibodies to <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> Merozoite Surface Protein 5 in Indonesia: Speciesâ€5pecific and Crossâ€Reactive Responses. Journal of Infectious Diseases, 2008, 198, 134-142.	4.0	65
188	Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17097-17102.	7.1	235
189	The Relationship between Age and the Manifestations of and Mortality Associated with Severe Malaria. Clinical Infectious Diseases, 2008, 47, 151-157.	5.8	214
190	Pharmacokinetics of <scp>l</scp> -Arginine in Adults with Moderately Severe Malaria. Antimicrobial Agents and Chemotherapy, 2008, 52, 4381-4387.	3.2	33
191	Adverse Pregnancy Outcomes in an Area Where Multidrugâ€Resistant <i>Plasmodium vivax</i> and <i>Plasmodium falciparum</i> Infections Are Endemic. Clinical Infectious Diseases, 2008, 46, 1374-1381.	5.8	131
192	Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Critical Care Medicine, 2008, 36, 448-454.	0.9	54
193	Fatal communityâ€associated methicillinâ€resistant Staphylococcus aureus pneumonia after influenza. Medical Journal of Australia, 2008, 188, 61-61.	1.7	32
194	Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia. PLoS Medicine, 2008, 5, e128.	8.4	510
195	Safety Profile of L-Arginine Infusion in Moderately Severe Falciparum Malaria. PLoS ONE, 2008, 3, e2347.	2.5	28
196	Improving Case Definitions for Severe Malaria. PLoS Medicine, 2007, 4, e267.	8.4	28
197	Impaired nitric oxide bioavailability and <scp>l</scp> -arginine–reversible endothelial dysfunction in adults with falciparum malaria. Journal of Experimental Medicine, 2007, 204, 2693-2704.	8.5	270
198	Lung Injury in Vivax Malaria: Pathophysiological Evidence for Pulmonary Vascular Sequestration and Posttreatment Alveolar apillary Inflammation. Journal of Infectious Diseases, 2007, 195, 589-596.	4.0	172

#	Article	IF	CITATIONS
199	Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms. PLoS ONE, 2007, 2, e1089.	2.5	187
200	Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	445
201	Improving the availability of artesunate for treatment of severe malaria. Medical Journal of Australia, 2006, 184, 3-4.	1.7	9
202	Malaria tolerance – for whom the cell tolls?. Trends in Parasitology, 2006, 22, 371-377.	3.3	68
203	Elevated Plasma Phenylalanine in Severe Malaria and Implications for Pathophysiology of Neurological Complications. Infection and Immunity, 2006, 74, 3355-3359.	2.2	53
204	Normal spirometry, gas transfer and lung volume values in Papua, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health, 2006, 37, 571-7.	1.0	6
205	Community-acquired pneumonia in northern Australia: low mortality in a tropical region using locally-developed treatment guidelines. International Journal of Infectious Diseases, 2005, 9, 15-20.	3.3	32
206	Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea. American Journal of Tropical Medicine and Hygiene, 2005, 72, 708-13.	1.4	7
207	Adjunctive Granulocyte Colony‣timulating Factor for Treatment of Septic Shock Due to Melioidosis. Clinical Infectious Diseases, 2004, 38, 32-37.	5.8	100
208	Nitric Oxide Production and Nitric Oxide Synthase Activity in Malaria-Exposed Papua New Guinean Children and Adults Show Longitudinal Stability and No Association with Parasitemia. Infection and Immunity, 2004, 72, 6932-6938.	2.2	24
209	Epidemiology of community-acquired and nosocomial bloodstream infections in tropical Australia: a 12-month prospective study. Tropical Medicine and International Health, 2004, 9, 795-804.	2.3	60
210	Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia. Tropical Medicine and International Health, 2004, 9, 1167-1174.	2.3	151
211	Outcomes of Patients with Melioidosis Treated with Meropenem. Antimicrobial Agents and Chemotherapy, 2004, 48, 1763-1765.	3.2	78
212	C-reactive protein in the diagnosis of melioidosis. American Journal of Tropical Medicine and Hygiene, 2004, 70, 580-2.	1.4	8
213	Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet, The, 2003, 361, 676-678.	13.7	154
214	Immunoglobulin G (IgG) Responses toPlasmodium falciparumGlycosylphosphatidylinositols Are Shortâ€Lived and Predominantly of the IgG3Subclass. Journal of Infectious Diseases, 2003, 187, 862-865.	4.0	44
215	Plasma Interleukin-12 in Malaria-Tolerant Papua New Guineans: Inverse Correlation with Plasmodium falciparum Parasitemia and Peripheral Blood Mononuclear Cell Nitric Oxide Synthase Activity. Infection and Immunity, 2003, 71, 6354-6357.	2.2	15
216	Nitric Oxide Production and Mononuclear Cell Nitric Oxide Synthase Activity in Malaria-Tolerant Papuan Adults. Infection and Immunity, 2003, 71, 3682-3689.	2.2	32

#	Article	IF	CITATIONS
217	Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism: relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population. American Journal of Tropical Medicine and Hygiene, 2003, 69, 569-73.	1.4	10
218	Pulmonary Manifestations of Uncomplicated Falciparum and Vivax Malaria: Cough, Small Airways Obstruction, Impaired Gas Transfer, and Increased Pulmonary Phagocytic Activity. Journal of Infectious Diseases, 2002, 185, 1326-1334.	4.0	128
219	Antibodies to Plasmodium falciparum Glycosylphosphatidylinositols: Inverse Association with Tolerance of Parasitemia in Papua New Guinean Children and Adults. Infection and Immunity, 2002, 70, 5052-5057.	2.2	66
220	Community-Acquired Bacteremic Acinetobacter Pneumonia in Tropical Australia Is Caused by Diverse Strains of Acinetobacter baumannii, with Carriage in the Throat in At-Risk Groups. Journal of Clinical Microbiology, 2002, 40, 685-686.	3.9	117
221	Enteric pathogens, intestinal permeability and nitric oxide production in acute gastroenteritis. Pediatric Infectious Disease Journal, 2002, 21, 730-739.	2.0	59
222	Systemic Nitric Oxide Production in Human Malaria: I. Analysis of NO Metabolites in Biological Fluids. , 2002, 72, 461-468.		5
223	A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet, The, 2002, 360, 1468-1475.	13.7	176
224	Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations. Antimicrobial Agents and Chemotherapy, 2002, 46, 3947-3953.	3.2	111
225	Paraplegia secondary to Burkholderia pseudomallei myelitis: A case report. Archives of Physical Medicine and Rehabilitation, 2001, 82, 1630-1632.	0.9	6
226	Will the high rates of post-treatment sexual stage parasitaemia seen in malaria-endemic areas make the optiMAL antigen test unreliable in predicting malaria treatment outcome?. British Journal of Haematology, 2001, 113, 255-256.	2.5	7
227	Title is missing!. Sepsis, 2001, 4, 217-231.	0.5	8
228	Persistent ICT Malaria P.f/P.v Panmalarial and HRP2 Antigen Reactivity after Treatment of Plasmodium falciparum Malaria Is Associated with Gametocytemia and Results in False-Positive Diagnoses of Plasmodium vivax in Convalescence. Journal of Clinical Microbiology, 2001, 39, 1025-1031.	3.9	93
229	The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Tropica, 2000, 74, 121-127.	2.0	203
230	[6] Measuring nitric oxide production in human clinical studies. Methods in Enzymology, 1999, 301, 49-61.	1.0	122
231	Field Evaluation of the ICT Malaria P.f/P.v Immunochromatographic Test for Detection of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> in Patients with a Presumptive Clinical Diagnosis of Malaria in Eastern Indonesia. Journal of Clinical Microbiology, 1999, 37, 2412-2417.	3.9	149
232	An expanded histatin gene polymorphism and test of a possible disease resistant phenotype. , 1997, 10, 58-64.		2
233	Seroepidemiology of Rickettsia typhi, Spotted Fever Group Rickettsiae, and Coxiella burnetti Infection in Pregnant Women from Urban Tanzania. American Journal of Tropical Medicine and Hygiene, 1997, 57, 187-189.	1.4	24
234	Open-label titration study of the safety of RMP-7 in patients with the acquired immune deficiency syndrome. International Journal of Antimicrobial Agents, 1996, 6, 183-187.	2.5	3

#	Article	IF	CITATIONS
235	Neurological Melioidosis: Seven Cases from the Northern Territory of Australia. Clinical Infectious Diseases, 1992, 15, 163-169.	5.8	74
236	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	27.8	1,494
237	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16